Rapport Therapeutics initiated Phase 3 trials (FOCUS 1 and FOCUS 2) for its drug RAP-219 targeting focal onset seizures, building on promising Phase 2a results showing significant seizure reduction. The company also advances trials for bipolar mania and is developing a long-acting injectable form of RAP-219, with topline bipolar mania data expected in October 2026. Financially, Rapport ended Q2 2026 with $436.1 million in cash, supporting operations into late 2029 despite a net loss of $56.6 million due to increased R&D and operational expenses. These developments position RAP-219 as a potential precision medicine breakthrough in neurological disorders, with further expansion planned into primary generalized tonic-clonic seizures and chronic pain treatments.
Tron founder Justin Sun has unstaked a total of 10,000 ETH from the Lido liquid staking protocol since August 26, moving about $12.3 million of that ether to Poloniex, an exchange he supports. While this shows some liquidity being freed up, Sun still...
Starknet has introduced Shieldnet, a new privacy framework called STRK20 that protects transaction details for 45 ERC-20 tokens on its Ethereum Layer 2 network. Using zero-knowledge proofs, Shieldnet encrypts transaction data, hiding sender, receiver...
Microchip Technology reported strong revenue growth and margin recovery in the first quarter of FY2027, driven by accelerating data center demand and growth in aerospace and defense sectors. The company’s valuation is expected to improve significantl...
SoFi Technologies is rated a Strong Buy with a $23 price target due to its successful transition to a diversified financial platform. Key growth drivers include lending, the Loan Platform Business, and expanding financial services, along with contrib...
Metaplanet capped its Series 10 executive option pool at 319.5 million shares after removing an automatic adjustment that had increased dilution following its 2024 Bitcoin treasury pivot. CEO Simon Gerovich exercised 92,000 rights, creating 64 millio...
